205 related articles for article (PubMed ID: 34147597)
1. Improvement of PI-RADS-dependent prostate cancer classification by quantitative image assessment using radiomics or mean ADC.
Zhang KS; Schelb P; Kohl S; Radtke JP; Wiesenfarth M; Schimmöller L; Kuder TA; Stenzinger A; Hohenfellner M; Schlemmer HP; Maier-Hein K; Bonekamp D
Magn Reson Imaging; 2021 Oct; 82():9-17. PubMed ID: 34147597
[TBL] [Abstract][Full Text] [Related]
2. Radiomic Machine Learning for Characterization of Prostate Lesions with MRI: Comparison to ADC Values.
Bonekamp D; Kohl S; Wiesenfarth M; Schelb P; Radtke JP; Götz M; Kickingereder P; Yaqubi K; Hitthaler B; Gählert N; Kuder TA; Deister F; Freitag M; Hohenfellner M; Hadaschik BA; Schlemmer HP; Maier-Hein KH
Radiology; 2018 Oct; 289(1):128-137. PubMed ID: 30063191
[TBL] [Abstract][Full Text] [Related]
3. A radiomics machine learning-based redefining score robustly identifies clinically significant prostate cancer in equivocal PI-RADS score 3 lesions.
Hou Y; Bao ML; Wu CJ; Zhang J; Zhang YD; Shi HB
Abdom Radiol (NY); 2020 Dec; 45(12):4223-4234. PubMed ID: 32740863
[TBL] [Abstract][Full Text] [Related]
4. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
[TBL] [Abstract][Full Text] [Related]
5. Utility of machine learning of apparent diffusion coefficient (ADC) and T2-weighted (T2W) radiomic features in PI-RADS version 2.1 category 3 lesions to predict prostate cancer diagnosis.
Lim CS; Abreu-Gomez J; Thornhill R; James N; Al Kindi A; Lim AS; Schieda N
Abdom Radiol (NY); 2021 Dec; 46(12):5647-5658. PubMed ID: 34467426
[TBL] [Abstract][Full Text] [Related]
6. Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment.
Schelb P; Kohl S; Radtke JP; Wiesenfarth M; Kickingereder P; Bickelhaupt S; Kuder TA; Stenzinger A; Hohenfellner M; Schlemmer HP; Maier-Hein KH; Bonekamp D
Radiology; 2019 Dec; 293(3):607-617. PubMed ID: 31592731
[TBL] [Abstract][Full Text] [Related]
7. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
8. Quantitative Analysis of Diffusion Weighted Imaging May Improve Risk Stratification of Prostatic Transition Zone Lesions.
Engel H; Oerther B; Reisert M; Kellner E; Sigle A; Gratzke C; Bronsert P; Krauss T; Bamberg F; Benndorf M
In Vivo; 2022; 36(5):2323-2331. PubMed ID: 36099133
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK
AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220
[No Abstract] [Full Text] [Related]
10. PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists.
Bhayana R; O'Shea A; Anderson MA; Bradley WR; Gottumukkala RV; Mojtahed A; Pierce TT; Harisinghani M
AJR Am J Roentgenol; 2021 Jul; 217(1):141-151. PubMed ID: 32903060
[No Abstract] [Full Text] [Related]
11. Magnetic Resonance Imaging Radiomics-Based Machine Learning Prediction of Clinically Significant Prostate Cancer in Equivocal PI-RADS 3 Lesions.
Hectors SJ; Chen C; Chen J; Wang J; Gordon S; Yu M; Al Hussein Al Awamlh B; Sabuncu MR; Margolis DJA; Hu JC
J Magn Reson Imaging; 2021 Nov; 54(5):1466-1473. PubMed ID: 33970516
[TBL] [Abstract][Full Text] [Related]
12. Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.
Abreu-Gomez J; Walker D; Alotaibi T; McInnes MDF; Flood TA; Schieda N
Eur Radiol; 2020 Aug; 30(8):4251-4261. PubMed ID: 32211965
[TBL] [Abstract][Full Text] [Related]
13. Multiparametric MRI for Prostate Cancer Characterization: Combined Use of Radiomics Model with PI-RADS and Clinical Parameters.
Woźnicki P; Westhoff N; Huber T; Riffel P; Froelich MF; Gresser E; von Hardenberg J; Mühlberg A; Michel MS; Schoenberg SO; Nörenberg D
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630787
[TBL] [Abstract][Full Text] [Related]
14. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
[TBL] [Abstract][Full Text] [Related]
15. Transition zone prostate cancer: Logistic regression and machine-learning models of quantitative ADC, shape and texture features are highly accurate for diagnosis.
Wu M; Krishna S; Thornhill RE; Flood TA; McInnes MDF; Schieda N
J Magn Reson Imaging; 2019 Sep; 50(3):940-950. PubMed ID: 30701625
[TBL] [Abstract][Full Text] [Related]
16. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
[TBL] [Abstract][Full Text] [Related]
17. Machine learning-based analysis of MR radiomics can help to improve the diagnostic performance of PI-RADS v2 in clinically relevant prostate cancer.
Wang J; Wu CJ; Bao ML; Zhang J; Wang XN; Zhang YD
Eur Radiol; 2017 Oct; 27(10):4082-4090. PubMed ID: 28374077
[TBL] [Abstract][Full Text] [Related]
18. Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems.
Gaur S; Harmon S; Rosenblum L; Greer MD; Mehralivand S; Coskun M; Merino MJ; Wood BJ; Shih JH; Pinto PA; Choyke PL; Turkbey B
AJR Am J Roentgenol; 2018 Jul; 211(1):W33-W41. PubMed ID: 29733695
[TBL] [Abstract][Full Text] [Related]
19. Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.
Yim JH; Kim CK; Kim JH
J Magn Reson Imaging; 2018 Apr; 47(4):1072-1079. PubMed ID: 28901655
[TBL] [Abstract][Full Text] [Related]
20. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer.
Lin WC; Westphalen AC; Silva GE; Chodraui Filho S; Reis RB; Muglia VF
Abdom Radiol (NY); 2016 Nov; 41(11):2209-2217. PubMed ID: 27364781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
